Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease
Open Access
- 18 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (12) , e033278
Abstract
Background: Most adults with sickle cell disease will experience a silent cerebral infarction (SCI) or overt stroke. Identifying patient subgroups with increased stroke incidence is important for future clinical trials focused on stroke prevention. Our 3‐center prospective cohort study tested the primary hypothesis that adults with sickle cell disease and SCIs have a greater incidence of new stroke or SCI compared with those without SCI. A secondary aim focused on identifying additional risk factors for progressive infarcts, particularly traditional risk factors for stroke in adults. Methods and Results: This observational study included adults with sickle cell disease and no history of stroke. Magnetic resonance imaging scans of the brain completed at baseline and >1 year later were reviewed by 3 radiologists for baseline SCIs and new or progressive infarcts on follow‐up magnetic resonance imaging. Stroke risk factors were abstracted from the medical chart. Time‐to‐event analysis was utilized for progressive infarcts. Median age was 24.1 years; 45.3% of 95 participants had SCIs on baseline magnetic resonance imaging. Progressive infarcts were present in 17 participants (17.9%), and the median follow‐up was 2.1 years. Incidence of new infarcts was 11.95 per 100 patient‐years (6.17–20.88) versus 3.74 per 100 patient‐years (1.21–8.73) in those with versus without prior SCI. Multivariable Cox regression showed that baseline SCI predicts progressive infarcts (hazard ratio, 3.46 [95% CI, 1.05–11.39]; P =0.041); baseline hypertension was also associated with progressive infarcts (hazard ratio, 3.23 [95% CI, 1.16–9.51]; P =0.025). Conclusions: Selecting individuals with SCIs and hypertension for stroke prevention trials in sickle cell disease may enrich the study population with those at highest risk for infarct recurrence.Keywords
This publication has 23 references indexed in Scilit:
- Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trialThe Lancet Haematology, 2022
- Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preferenceBritish Journal of Haematology, 2017
- Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemiaBritish Journal of Haematology, 2016
- Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialThe Lancet, 2016
- Guidelines for the Primary Prevention of StrokeStroke, 2014
- Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell AnemiaNew England Journal of Medicine, 2014
- Population Estimates of Sickle Cell Disease in the U.S.American Journal of Preventive Medicine, 2010
- Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell DiseaseNew England Journal of Medicine, 2005
- Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler UltrasonographyNew England Journal of Medicine, 1998
- Natural History of Blood Pressure in Sickle Cell Disease: Risks for Stroke and Death Associated with Relative Hypertension in Sickle Cell AnemiaThe American Journal of Medicine, 1997